# Olink

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/olink
Canonical HTML page: https://getbiobrief.com/entity/olink

## Recent coverage (1 stories)

### Seer Surpasses Q4 Earnings Estimates Amid Proteomics Market Expansion
2026-02-27 00:53:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Seer (NASDAQ: SEER) reported quarterly earnings that exceeded analyst expectations by $0.03 per share, signaling resilience in the life sciences tools sector. The results highlight growing adoption of the company's Proteograph Product Suite as researchers increasingly prioritize high-resolution proteomics in drug discovery.
Full story: https://getbiobrief.com/story/seer-nasdaq-seer-q4-earnings-beat-proteomics-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.